Medically reviewed by Jay N. Yepuri, MD PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow disease progression and manage ...

(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...

Please provide your email address to receive an email when new articles are posted on . More patients on elafibranor compared with placebo achieved biochemical response, with a 47% treatment benefit.

Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...

The largest phase 3 trial aimed at relieving cholestatic pruritus in PBC shows significantly reduced itching and improved ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients with primary biliary cholangitis (PBC), the randomized phase III GLISTEN ...

BOSTON -- An investigational dual peroxisome proliferator-activated receptor (PPAR) agonist appeared effective as a second-line option for primary biliary cholangitis (PBC), according to phase III ...

This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Initial data from ASSURE showed 70% of the 148 patients who completed 12 months of treatment with seladelpar achieved the composite response endpoint. Seladelpar was associated with improvement in ...